41877-24-1

Basic information

• Product Name: 1-(5-Bromo-2-nitro-phenyl)-ethanone
• Synonyms: 1-(5-Bromo-2-nitro-phenyl)-ethanone;5'-Bromo-2'-nitroacetophenone;5-BroMo-2-nitroacetophenone (1-(5-broMo-2-nitrophenyl)-ethanone);1-(5-Bromo-2-nitrophenyl)ethan-1-one;1-(5-Bromo-2-nitrophenyl)
• CAS NO: 41877-24-1
• Molecular Formula: C₈H₆BrNO₃
• Molecular Weight: 244.05
• Mol File: 41877-24-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 345.6°C at 760 mmHg
• Flash Point: 162.8°C
• Appearance: /
• Density: 1.637g/cm³
• Vapor Pressure: 6.07E-05mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(5-Bromo-2-nitro-phenyl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-Bromo-2-nitro-phenyl)-ethanone(41877-24-1)
• EPA Substance Registry System: 1-(5-Bromo-2-nitro-phenyl)-ethanone(41877-24-1)

Safety Data

• Hazardous Substances Data: 41877-24-1(Hazardous Substances Data)

Usage

General Description

1-(5-Bromo-2-nitro-phenyl)-ethanone, also known as 2-Acetyl-5-bromo-2-nitroaniliate, is a chemical compound with the molecular formula C8H6BrNO4. It is a yellow crystalline solid with a melting point of 102-106°C. 1-(5-Bromo-2-nitro-phenyl)-ethanone is commonly used in organic synthesis and pharmaceutical research as an intermediate in the production of various pharmaceuticals and agrochemicals. It is also used as a reagent in the synthesis of other organic compounds. The presence of a nitro group and a bromo group in its chemical structure makes it a versatile building block for the preparation of various biologically active compounds. 1-(5-Bromo-2-nitro-phenyl)-ethanone is known for its moderate toxicity and should be handled with care in a laboratory setting.

InChI:InChI=1/C8H6BrNO3/c1-5(11)7-4-6(9)2-3-8(7)10(12)13/h2-4H,1H3

Upstream product

• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 861611-98-5 1-(2-nitroamino-phenyl)-ethanone 
• 1020575-89-6 1-(5-bromo-2-nitrophenyl)ethane-1-ol 
• 16994-13-1 3-amino-6-nitroacetophenone 
• 56759-31-0 1-(3-bromo-2-nitrophenyl)ethanone 

Downstream Products

• 1020576-02-6 ethyl 6-bromo-4-methyl-2-quinolinecarboxylate 
• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 914105-66-1 2,3-dibromo-1-(5-bromo-2-nitrophenyl)-3-(4-bromophenyl)propan-1-one 
• 914105-71-8 2,3-dibromo-1-(5-bromo-2-nitrophenyl)-3-(3-bromophenyl)propan-1-one 
• 914105-76-3 3-(5-bromo-2-nitrophenyl)-5-(4-bromophenyl)isoxazole 
• 914105-82-1 3-(5-bromo-2-nitrophenyl)-5-(3-bromophenyl)isoxazole 
• 914105-87-6 3-(5-cyano-2-nitrophenyl)-5-(4-cyanophenyl)isoxazole 
• 914105-94-5 3-(5-cyano-2-nitrophenyl)-5-(3-cyanophenyl)isoxazole 
• 1020575-89-6 1-(5-bromo-2-nitrophenyl)ethane-1-ol 
• 1020575-82-9 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-4-methyl-2-quinolinecarboxylic acid 
• 1020577-05-2 ethyl 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-4-methyl-2-quinazolinecarboxylate 
• 1020576-16-2 ethyl 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-4-methyl-2-quinolinecarboxylate 
• 1020576-84-4 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-4-methyl-2-quinazolinecarboxylic acid 

Relevant articles and documents

Discovery of Chromane-6-Sulfonamide Derivative as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist

Interleukin-17 (IL-17) is a proinflammatory cytokine that plays a dominant role in inflammation, autoimmunity, and host defense. RORγt is a key transcription factor mediating T helper 17 (Th17) cell differentiation and IL-17 production, which is able to activate CD8+ T cells and elicit antitumor efficacy. A series of sulfonamide derivatives as novel RORγt inverse agonists were designed and synthesized. Using GSK2981278 (phase II) as a starting point, we engineered structural modifications that significantly improved the activity and pharmacokinetic profile. In animal studies, oral administration of compound d3 showed a robust and dose-dependent inhibition of the IL-17A cytokine expression in a mouse imiquimod-induced skin inflammation model. Docking analysis of the binding mode revealed that the compound d3 occupied the active pocket suitably. Thus, compound d3 was selected as a clinical compound for the treatment of Th17-driven autoimmune diseases.

A 1H-indazole derivatives preparation method

The invention provides a method for preparing 3-methyl-5-R-1H-indazole easily, safely and efficiently without performing any hydrazine hydrate reflux heating reaction or purifying a product and making the product pass through a column. The method at least comprises the following steps of: a, performing a diazo-reaction on 2-amino-5-R-hypnone serving as a raw material or an intermediate under the condition of an acid solution to generate a diazo salt; b, slowly adding a stannous chloride-hydrate hydrochloric acid solution into the diazo salt obtained in the step a for reacting to generate a 3-methyl-5-R-1H-indazole solution; and c, cooling the solution obtained in the step b under the condition that the pH value is 8-9, and precipitating a product out, wherein R in the steps above represents H or a halogen element.

Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test

To develop non-basic melanin-concentrating hormone receptor 1 (MCHR1) antagonists with a high probability of target selectivity and therapeutic window, we explored neutral bicyclic motifs that could replace the previously reported imidazo[1,2-a]pyridine or 1H-benzimidazole motif. The results indicated that the binding affinity of a chemically neutral 2H-indazole derivative 8a with MCHR1 (hMCHR1: IC50 = 35 nM) was comparable to that of the imidazopyridine and benzimidazole derivatives (1 and 2, respectively) reported so far. However, 8a was positive in the Ames test using TA1537 in S9- condition. Based on a putative intercalation of 8a with DNA, we introduced a sterically-hindering cyclopropyl group on the indazole ring to decrease planarity, which led to the discovery of 1-(2-cyclopropyl-3-methyl-2H-indazol-5-yl)-4-{[5-(trifluoromethyl)thiophen-3-yl]methoxy}pyridin-2(1H)-one 8l without mutagenicity in TA1537. Compound 8l exerted significant antiobesity effects in diet-induced obese F344 rats and exhibited promising safety profile.